Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA)

Официальное название

Neoadjuvant Therapy With Weekly Utidelone Combined With Cisplatin for Patients With Breast Cancer (NeoURANIA): A Multi-center, Prospective Study

Обзор

This study is a prospective, multi-center, single-arm, two-cohort, exploratory study, aiming to explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in breast cancer patients.

Подробное описание

Explore the effectiveness and safety of neoadjuvant treatment with weekly utidelone combined with cisplatin in high risk early, locally advanced and Inflammatory breast cancer patients.

Вмешательства

• Препарат utidelone
  utidelone 50mg／m2，ivgtt，d1，8，15，22, q28d, up to 4 cycle；
• Препарат Cisplatin
  cisplatin25mg/m2，ivgtt，d1，8，15；q28d, up to 4 cycle.
• Препарат Trastuzumab
  Trastuzumab 8mg/kg, ivgtt, d1, then 6mg/kg, q21d or Trastuzumab 4mg/kg, ivgtt, d1, then 2mg/kg, q7d or Trastuzumab Injection（Subcutaneous Injection）600mg，subcutaneous Injection，d1，q21d
• Препарат Pertuzumab
  Pertuzumab 840mg, ivgtt, d1, then 420mg, q21d or Pertuzumab/trastuzumab/hyaluronidase

Первичные конечные точки

• pCR [Срок оценки: through surgery completion, an average of 16 weeks]

Вторичные конечные точки (12)

• breast pCR [Срок оценки: through surgery completion, an average of 16 weeks]
• RCB 0/I rate [Срок оценки: through surgery completion, an average of 16 weeks]
• RCB class [Срок оценки: through surgery completion, an average of 16 weeks]
• Rate of lymph node negative [Срок оценки: through surgery completion, an average of 16 weeks]
• ORR by physical examination [Срок оценки: After completing neoadjuvant therapy before surgery, an average of 16 weeks]
• ORR by MRI [Срок оценки: After completing neoadjuvant therapy before surgery, an average of 16 weeks]
• CBR by physical examination [Срок оценки: After completing neoadjuvant therapy before surgery, an average of 16 weeks]
• CBR by MRI [Срок оценки: After completing neoadjuvant therapy before surgery, an average of 16 weeks]
• iDFS [Срок оценки: 2year,3year,5year,8year,10year]
• EFS [Срок оценки: 2year,3year,5year,8year,10year]
• DDFS [Срок оценки: 2year,3year,5year,8year,10year]
• OS [Срок оценки: 2year,3year,5year,8year,10year]

Критерии участия

Критерии включения

• Age ≥18 years old;
• Primary invasive breast cancer confirmed by pathology; Before neoadjuvant therapy, the primary breast lesion was larger than 2cm(cT2-T4a-d, according to the anatomical staging of AJCC 8th edition), or the clinical images of lymph nodes considered metastasis or pathologically confirmed metastasis (CN+); or patients whose primary breast lesions are more than 1cm and less than 2cm, and whose lymph nodes have not metastasized (cT1cN0) must meet one of the following conditions: hormone receptor negative, HER2 positive, or ki67 greater than 20%. If bilateral breast cancer is found at the same time, it can be admitted to the group, but it is necessary to determine which side of the lesion is to be evaluated before taking the drug;
• According to the RECIST version 1.1 standard (see Annex I), there is at least one measurable lesion before neoadjuvant therapy;
• The score of ECOG is 0 or 1;
• During neoadjuvant therapy, ovarian function suppression can be given at the same time;
• The hematological examination and blood biochemical examination should meet the following requirements: white blood cell count (WBC)≥3.0×109/L, neutrophil count (ANC)≥1.5×109/L and platelet count (PLT) ≥ 75× 109/L; Hemoglobin (HB) ≥ 80g/L; Total bilirubin (TBIL)≤1.5× upper limit of normal value (ULN), AST(sGOT), ALT(sGPT)≤2×ULN and creatinine (Cr) ≤ 1.5× ULN;
• creatinine clearance rate ≥50mL/min(Cockcroft-Gault formula);
• Subjects voluntarily joined the study, signed the informed consent form, and had good compliance and cooperated with the follow-up.

Критерии исключения

• Patients during pregnancy and lactation, patients with fertility and positive baseline pregnancy test, or women of childbearing age who are unwilling to take effective contraceptive measures during the whole trial period;
• There is distant metastasis of breast cancer confirmed by imaging or pathology before enrollment;
• There is evidence of sensory or motor nerve diseases;
• Severe cardiopulmonary insufficiency, severe hepatic and renal insufficiency, severe concomitant disease or active infection, including known HIV infection;
• allergic to the research drug or its auxiliary materials;
• Arterial/venous thrombotic events, such as cerebrovascular accident (including transient ischemic attack), deep venous thrombosis and pulmonary embolism, occurred within 6 months before the start of the study;
• Previous history of other malignant tumors, except the cured basal cell carcinoma of the skin, carcinoma in situ of the cervix, and the second primary malignant tumor with high 5-year recurrence-free survival rate determined by researchers;
• According to the researcher's judgment, there are accompanying diseases (including but not limited to uncontrollable hypertension, severe diabetes, active infection, thyroid disease, etc.) that seriously endanger the patient's safety or affect the patient's completion of the study, and any other circumstances that the researcher judges that the patient is not suitable for participating in this study.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Нет

Дизайн исследования

Распределение

Нерандомизированное

Модель

Параллельные группы

Маскирование

Открытое

Основная цель

Лечение

Центры проведения

Китай · 2 центра

• Renji Hospital, School of Medicine, Shanghai Jiao Tong University — Шанхай
• Renji Hospital — Шанхай

Идентификаторы

NCT: NCT06510465 · SHPD009

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗